Drug intelligence / Profile preview

Jeeni

Development stage: Preclinical
Lead developer: Alvit LCS Pharma
Modality: Small Molecules
Administration: Inhalation

Overview

Jeeni is a proprietary line of vaporized cannabis oil blends developed by Alvit LCS Pharma for delivery via a specialized vape pen. The product line utilizes proprietary cannabinoid formulations intended for therapeutic inhalation. While specific molecular targets are not explicitly disclosed by the developer, the active components typically function as agonists of the endocannabinoid system, specifically targeting Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). Jeeni is positioned within Alvit's portfolio of medical and consumer-facing cannabis brands and is currently described as being under development or recently approved for clinical evaluation in Israel.

Brand names: Jeeni
Other names: JEENI

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Jeeni.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jeeni.

Explore the full profile